Mekhail TM - Search Results

1

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Choueiri TK, et al. Among authors: mekhail tm. Cancer. 2006 Dec 1;107(11):2609-16. doi: 10.1002/cncr.22290. Cancer. 2006. PMID: 17075879 Free article. Clinical Trial.

2

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.

Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Choueiri TK, et al. Among authors: mekhail tm. Ann Oncol. 2007 Feb;18(2):249-55. doi: 10.1093/annonc/mdl371. Epub 2006 Oct 23. Ann Oncol. 2007. PMID: 17060490 Free article.

3

Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.

Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T. Kalmadi S, et al. Invest New Drugs. 2007 Jun;25(3):211-6. doi: 10.1007/s10637-006-9025-4. Epub 2006 Nov 11. Invest New Drugs. 2007. PMID: 17103043 Clinical Trial.

4

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI. Tamaskar I, et al. Ann Oncol. 2008 Feb;19(2):265-8. doi: 10.1093/annonc/mdm483. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962201 Free article.

5

Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.

Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM. Tamaskar I, et al. Invest New Drugs. 2008 Dec;26(6):553-9. doi: 10.1007/s10637-008-9153-0. Epub 2008 Jul 15. Invest New Drugs. 2008. PMID: 18626572 Clinical Trial.

6

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Mekhail TM, et al. J Clin Oncol. 2005 Feb 1;23(4):832-41. doi: 10.1200/JCO.2005.05.179. J Clin Oncol. 2005. PMID: 15681528

7

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI. Golshayan AR, et al. Among authors: mekhail tm. J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064974

8

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.

Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, Bukowski RM. Mekhail T, et al. Cancer. 2003 Jan 1;97(1):170-8. doi: 10.1002/cncr.10991. Cancer. 2003. PMID: 12491518 Free article. Clinical Trial.

9

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Hutson TE, Molto L, Mekhail T, Elson P, Finke J, Tannenbaum C, Borden E, Dreicer R, Olencki T, Bukowski RM. Hutson TE, et al. Clin Cancer Res. 2003 Apr;9(4):1354-60. Clin Cancer Res. 2003. PMID: 12684404 Clinical Trial.

10

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.

Hutson TE, Ganapathi R, Elson P, Mekhail T, Olencki T, Budd GT, Bukowski RM. Hutson TE, et al. Invest New Drugs. 2004 Aug;22(3):277-84. doi: 10.1023/B:DRUG.0000026253.02502.ce. Invest New Drugs. 2004. PMID: 15122074 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters